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Abstract
Introduction—African Americans’ (AAs) late-onset Alzheimer’s disease (LOAD) genetic risk 
profile is incompletely understood. Including clinical covariates in genetic analyses using 
informed conditioning might improve study power.
Methods—We conducted a genome-wide association study (GWAS) in AAs employing informed 
conditioning in 1825 LOAD cases and 3784 cognitively normal controls. We derived a posterior 
liability conditioned on age, sex, diabetes status, current smoking status, educational attainment, 
and affection status, with parameters informed by external prevalence information. We assessed 
association between the posterior liability and a genome-wide set of single-nucleotide 
polymorphisms (SNPs), controlling for APOE and ABCA7, identified previously in a LOAD 
GWAS of AAs.
Results—Two SNPs at novel loci, rs112404845 (P = 3.8 × 10−8), upstream of COBL, and 
rs16961023 (P = 4.6 × 10−8), downstream of SLC10A2, obtained genome-wide significant 
evidence of association with the posterior liability.
Discussion—An informed conditioning approach can detect LOAD genetic associations in AAs 
not identified by traditional GWAS.
Keywords
Alzheimer’s disease; Genome-wide association study (GWAS); African Americans; Informed 
conditioning on clinical covariates; COBL; SLC10A2; APOE; ABCA7; Age; Sex differences; 
Diabetes; Smoking; Education; Resveratrol
1. Introduction
Late-onset Alzheimer’s disease (LOAD) in African Americans (AAs) is influenced by 
multiple genetic, clinical, and environmental factors [1–3]. AAs are at increased risk of 
LOAD compared with non-Hispanic whites [4–6]. Nonetheless, knowledge about the 
genetic architecture of LOAD comes disproportionately from studies of non-Hispanic 
whites. The relative lack of data presents a substantial barrier to understanding LOAD 
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mechanisms in AAs [3]. The APOE ε4 allele is a well-established genetic risk factor for 
LOAD in AAs [7]. Whereas >20 LOAD risk genes have been identified from genome-wide 
association studies (GWASs) for non-Hispanic whites, only two loci have been identified 
from GWAS for AAs [1,8]. A GWAS by Reitz et al. [1] found that, in addition to the APOE 
ε4 allele, a variant in the ABCA7 gene (rs115550680) was significantly associated with 
LOAD in AAs.
Most genetic association studies in LOAD, including those of AAs, adjust for age, sex, and 
population substructure (PC) only. For quantitative traits analyzed by linear regression, 
introducing other nonconfounding covariates into a genetic study could enhance detection of 
additional loci by accounting for some of the variance in the outcome. However, for case-
control association studies, including nonconfounding covariates in a logistic regression 
model can actually reduce power to detect an association because case-control ascertainment 
can create an artificial correlation between the genetic variant and a covariate, and each 
additional covariate reduces the precision of estimates [9,10]. Zaitlen et al. [11] recently 
showed that using an informed conditioning approach, nonconfounding covariates could be 
included in a case-control study with an increase in power compared with models that do not 
include covariates. Informed conditioning is based on the liability threshold model with 
parameters informed by external prevalence information. In this approach, first a liability 
model is constructed using covariates’ independent effect estimates, in the form of trait 
prevalences at different covariate levels. Next, an association is tested between a genetic 
variant and the residuals from the liability model [11]. Informed conditioning has been 
applied with success to other phenotypes including stroke, type-2 diabetes, prostate cancer, 
lung cancer, breast cancer, reheumatoid arthritis, age-related macular degeneration, and end-
stage kidney disease [11,12]. In the present study, we conducted a GWAS in the AA cohort 
of Reitz et al. [1], employing informed conditioning on LOAD status and several well-
established LOAD risk factors, obtaining genome-wide significant evidence of association at 
two novel loci.
2. Methods
2.1. Study population
Study population included 1825 well-characterized AA LOAD cases and 3784 cognitively 
normal AA controls from 9 Alzheimer’s Disease Genetic Consortium (ADGC) datasets: 
Adult Changes in Thought, Alzheimer’s Disease Centers 1&2 (ADC1&2), ADC3, ADGC, 
Chicago Health and Aging Project (CHAP), Indianapolis, Genetic and Environmental Risk 
Factors for Alzheimer Disease Among AAs (GenerAAtions), Multi-Institutional Research 
on Alzheimer Genetic Epidemiology (MIRAGE) 300k, and MIRAGE 660k. The ADGC 
dataset contained participants from several studies including the AA AD Genetics Study, the 
ADCs, CHAP, Mayo Clinic, Mount Sinai School of Medicine, Religious Orders Study/
Memory and Aging Project/Minority Aging Research Study (MARS)/Rush Clinical Core 
(CORE), University of Miami (UM)/Vanderbilt University (VU), University of Pittsburgh, 
Washington Heights Columbia Aging Project, and Washington University. A detailed 
description of subject recruitment and phenotyping has been described previously [1]. Two 
of these studies were family based (i.e., contained related participants: MIRAGE and 
Mez et al. Page 3
Alzheimers Dement. Author manuscript; available in PMC 2017 February 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
GenerAAtions), whereas the other studies included only unrelated participants. Age of 
symptom onset was available for most cases. For the remaining cases, surrogate age 
information was available (age at ascertainment for Indianapolis, age at diagnosis for CHAP 
and MARS/CORE, and age at death for autopsy cases from UM/VU). Age of last 
examination or age of death was available for controls. We excluded cases younger than age 
60. Ascertainment of additional risk factor data (educational attainment, diabetes status, and 
current smoking status) in each parent study has been described previously [13–20]. For the 
present study, we defined low educational attainment as ≤8 years of education. Because only 
a subset of the subjects from the ADGC dataset had additional risk factor data available, we 
divided the dataset into those with new risk factor data (ADGC1) and those without new risk 
factor data (ADGC2). Individuals were recruited under protocols approved by the 
appropriate institutional review boards.
2.2. Procedures
Details of genotyping (including platforms), quality control (including call rates, Hardy-
Weinberg equilibrium, discordance with ascertained sex and latent relatedness), and 
derivation of principal components to adjust for PCs were described previously [1]. Briefly, 
we used directly measured APOE genotypes. We estimated haplotypes using SHAPEIT [21] 
and then imputed allele dosages for each dataset separately using IMPUTE2 [22] and 1000 
Genomes reference haplotypes (March 2012). We excluded imputed single-nucleotide 
polymorphisms (SNPs) with an imputation quality estimate of R2 ≤0.40. In the unrelated 
cohorts, we did not exclude SNPs based on minor allele frequency (MAF) because their 
inclusion did not lead to P-value inflation. In the family-based cohorts, we excluded SNPs 
with MAFs <0.05. We derived principal components using EIGENSTRAT [23] separately 
for each dataset using a set of genotyped SNPs common to all genotyping platforms.
2.3. Calculation of the posterior mean residual liability score
An informed conditioning approach leverages external conditional prevalence data from the 
epidemiological literature. AA-specific prevalences of LOAD conditioned on LOAD risk 
factors (age, sex, education, current smoking status, and diabetes) have not been presented in 
the epidemiological literature. Therefore, we estimated the prevalences of LOAD in AAs 
>65 years of age, conditioned on a given LOAD risk factor (RF), based on published 
ancestry-nonspecific relative risks (RRs) of LOAD with respect to the RF [4–6,24,25], 
published prevalence of each RF (P(RF)) in AAs [26–29] (Supplementary Table 1), and 
estimated prevalence of LOAD in AAs (P(LOAD)) (Table 1). We assumed that RRs do not 
differ by ancestry [3,30–34]. The conditional prevalence of LOAD for a given RF, P(LOAD|
RF), is related to the RR as follows:
(1)
where ~ RF is the absence of the RF.
The law of total probability,
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(2)
can be used to rewrite the conditional prevalence as follows:
(3)
We used equation 3 to calculate the LOAD conditional prevalences in AAs for each of the 
five LOAD risk factors (Table 1).
An informed conditioning approach, described by Zaitlen et al. [11], models an unobserved 
underlying quantitative trait, ϕ, called the liability:
(4)
where cj is a parameter estimating the effect of a given covariate j on the liability scale, tj is 
the value of covariate j, and m is a parameter that determines the population prevalence p of 
LOAD at the covariate mean t̄j such that ϕ is the normal cumulative distribution function and 
ϕ (−m) = P (x > −m) = p. Finally, ε = γg + N (0,1) where γ is the effect size of the 
candidate SNP with genotype g normalized to mean 0 and N (0,1) is the standard normal 
distribution. Multiple covariates are treated independently, but parameters are estimated 
jointly. A subject is a case if ϕ ≥ 0 and is a control otherwise.
We estimated parameters for two models because the additional risk factor data were 
missing for a subset of study subjects. The first model included all LOAD risk factors and 
their corresponding external conditional prevalence estimates, whereas the second model 
included only age and sex as LOAD risk factors and their corresponding external conditional 
prevalence estimates. We used these models to calculate the posterior mean residual liability 
score (hereafter called the LOAD liability score) for each subject given their LOAD and risk 
factor status. We used the LTSOFT computer program [11,35] for modeling the LOAD 
liability and for generating the LOAD liability score.
2.4. Association analyses
For mean age, sex, current smoking status, diabetes status, mean education level, APOE ε4 
genotype, and rs115550680 MAF, we compared cases with controls in unadjusted models by 
meta-analyzing the ln odds ratio for categorical variables and standardized mean difference 
for continuous variables using a fixed-effects model with inverse variance weights. We 
conducted genome-wide association with the LOAD liability score using linear regression in 
each of the unrelated cohorts and linear generalized estimating equations (GEEs) in each 
family-based cohort, as the GEE method is robust to nonindependence of error terms within 
a family [36]. Association tests were adjusted for three PCs, APOE ε4 dosage, and dosage 
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of the minor allele of ABCA7 SNP rs115550680. Association tests were carried out using R 
version 3.1.2 software [37]. Results were combined across datasets by meta-analyzing the 
regression estimates after applying genomic control adjustments using a fixed-effects model 
with inverse variance weights, as implemented in METAL [38]. The test statistic was the 
meta-analyzed regression estimate divided by its standard error. Several post hoc analyses 
were conducted for top-ranked loci. We evaluated several logistic regression models using 
LOAD case-control status as the outcome with different sets of covariates. In addition, we 
analyzed a liability model that included the full set of clinical variables but that did not 
include APOE ε4 genotype and rs115550680 minor allele dosage as covariates.
3. Results
Table 2 shows characteristics for each dataset. In unadjusted models, older age, lower 
educational attainment, APOE ε4 genotype, and rs115550680 minor allele (G) dosage were 
associated with LOAD risk. Current smoking and diabetes were associated with reduced 
risk. Female sex was not associated with LOAD status. The conditional prevalence estimates 
of LOAD in AAs >65 years of age that were calculated based on published LOAD RF 
prevalences and LOAD RRs with respect to the RFs (Supplementary Table 1) are listed in 
Table 1.
A total of 19,725,427 SNPs passed quality control and were included in the GWAS. For 
individual datasets, the genomic inflation factor λ ranged from 0.984 to 1.127. There was no 
evidence of inflation of test statistics in the meta-analyzed LOAD liability model (λ = 0.993, 
Supplementary Fig. 1). We found genome-wide significant associations (P < = × 10−8) using 
informed conditioning in two distinct regions, 200-kb upstream of cordon-bleu WH2 repeat 
protein (COBL) and 30-kb downstream of solute carrier family 10, member 2 (SLC10A2) 
(Table 3). For the top SNP in each region (COBL: rs112404845, SLC10A2: rs16961023), 
the effect was in the same direction for all datasets (Figs. 1 and 2) and the final liability 
model showed a smaller P value than the logistic models by one to two orders of magnitude 
(Table 3).
Because both variants were imputed and relatively rare, we compared allele dosages from 
imputation with direct genotyping. For rs112404845 (imputation quality range [using the 
IMPUTE2 information metric]: 0.905–1.039), we Sanger sequenced 20 predicted risk-allele 
carriers and an equal number of noncarriers. We found perfect correlation between the 
imputed dosage and direct genotype. For rs16961023 (imputation quality range: 0.598–
0.917), we used a Taqman assay to directly genotype 35 predicted risk allele carriers and 
1720 noncarriers from the ADGC1 and ADGC2 datasets. As expected based on the 
imputation quality (ADGC1 = 0.704, ADGC2 = 0.679), the correlation between direct 
genotype and imputed dosage (ADGC1 = 0.736, ADGC2 = 0.565) was adequate. When we 
repeated our association analysis across all datasets, among subjects with imputed posterior 
probabilities >0.8, using best-guess genotype, there was a reduction in effect size from 0.41 
to 0.33.
Supplementary Table 2 shows SNPs with suggestive associations (P < = × 10−6) using 
informed conditioning. No loci identified as risk factors for LOAD in GWAS in white non-
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Hispanics showed suggestive associations. As a positive control, we compared the effect of 
the ABCA7 rs115550680 variant in a logistic model that controlled for age, sex, current 
smoking status, diabetes status, educational attainment, and PCs with the liability model. 
Using the informed conditioning approach, the P value decreased by a half order of 
magnitude in the liability model compared with a logistic model (Supplementary Table 3).
4. Discussion
In this study, we conducted a GWAS in AAs, employing informed conditioning on LOAD 
status and well-established LOAD risk factors including age, sex, diabetes status, current 
smoking status, and educational attainment. Our model is informed by external prevalence 
data from the epidemiological literature. Using this approach, which has been shown to 
outperform standard case-control association tests [11,12], we identified two genome-wide 
significant novel LOAD loci, upstream of COBL and downstream of SLC10A2.
COBL is predominantly expressed in brain, and its protein product regulates neuron 
morphogenesis. It mediates actin nucleation, ensuring that neurites form, elongate, and 
branch correctly to produce functional neuronal networks. In Cobl-deficient dissociated 
hippocampal neurons, neurite and dendritic branch point numbers were significantly reduced 
[39]. An SNP approximately 500-kb upstream of COBL was implicated in posttraumatic 
stress disorder in cohorts with European [40] and African ancestry [41]. Rs112404845, the 
top SNP in the COBL region in our study, is located 200-kb upstream of COBL and is 
present only in persons with African ancestry (MAF = 0.012 in the 1000 Genomes reference 
panel). This may explain why COBL has not been recognized previously as an AD risk 
gene. Variation at rs112404845 leads to a Pax-4 regulatory motif change. Rs113739092, an 
SNP in linkage disequilibrium with rs112404845 (r2 = 0.64) and which achieved a P value 
of 1.3 × 10−5, is an enhancer histone mark in brain [42].
SLC10A2 encodes a sodium/bile acid cotransporter that is essential for cholesterol 
homeostasis. Mutations in SLC10A2 have been found in cases of familial 
hypercholesterolemia [43]. Several other genes implicated by GWAS in LOAD pathogenesis 
function in cholesterol metabolism include APOE, CLU, ABCA7, and SORL1 [44]. 
Although its function is best understood in the small intestine [45], SLC10A2 also is 
expressed in brain [46]. Resveratrol, a chief constituent of red wine, inhibits SLC10A2 
expression and function through a Sirt1 (sirtuin 1)–independent manner [47]. Potentially an 
exciting therapy for LOAD, resveratrol reduces amyloid plaque pathology in AD animal 
models [48] and has been shown to be safe and well-tolerated in a large phase 2 LOAD 
clinical trial [49]. Although resveratrol’s antiamyloidogenic effects have been suggested to 
be mediated by Sirt1 [50], our findings indirectly suggest that resveratrol may affect AD 
through multiple mechanisms. Rs16961023, the most significantly associated SNP in the 
SLC10A2 region in our study, is located 30-kb downstream of SLC10A2. Variation at 
rs16961023 leads to an Egr-1 regulatory motif change [42]. In the 1000 Genomes reference 
panel, the rs16961023 minor allele is infrequent among persons with African ancestry (MAF 
= 0.02) and rare among persons with European ancestry (MAF = 0.004), but is common in 
East Asians (MAF = 0.15).We previously conducted a GWAS for LOAD case/control status 
in a Japanese cohort [51] but did not find any nominally associated SNPs at this locus. 
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Genetic association findings may be specific to a particular ethnic background, especially 
when variants are rare [52].
Current smoking has been found to increase LOAD risk in meta-analyses [24]; however, in 
this study, it was more frequent in LOAD controls than in LOAD cases when we combined 
the datasets. Ascertainment bias may explain this finding because our datasets are a mixture 
of clinic-and community-based studies. Cases disproportionately come from the clinic-based 
studies, whereas controls disproportionately come from the community-based studies. 
Typically, clinic-based cohorts have fewer vascular risk factors, including smoking, than 
their community-based counterparts [53]. Alternatively, survival bias may explain this 
finding, as smokers with LOAD may have died before entering the study [54]. Although 
early cross-sectional case-control studies observed that smoking was associated with a 
reduced risk of LOAD, a meta-analysis that included 23 longitudinal studies found that 
smoking increased risk [55]. That smoking occurs in our combined cohort at such a different 
relative rate than what is observed in the epidemiological literature emphasizes the 
importance of the informed conditioning approach, which makes use of external prevalence 
data.
Our study has several potential caveats. Because LOAD conditional prevalence data for AAs 
have not been reported, we estimated these values using available relative risk data that are 
not ancestry specific and therefore assumed that LOAD relative risks do not differ by 
ancestral population. Support for this assumption comes from review of the literature that 
shows the relative risks of dementia, LOAD, and/or cognitive decline for age, sex, diabetes 
status, smoking status, and educational attainment do not appear to differ significantly by 
ancestry [3,30–34]; however, this warrants further investigation. This concern is further 
lessened by a simulation study showing that moderate misspecification of model parameters 
did not reduce power and that even when parameters were misspecified by a large amount 
(up to 100%), the model still performed at least and logistic regression [11].
It should also be noted that the genome-wide significant variants near COBL and SLC10A2 
have low frequency (0.01–0.02). By comparison, SNPs with MAF <0.05 were not analyzed 
in the GWAS of Reitz et al. [1] because genotype imputation quality was poor for low-
frequency SNPs using the older 1000 Genomes reference panel. Using a newer reference 
panel, we were able to include low-frequency variants with improved imputation quality. For 
rs112404845, the top SNP in the COBL region, imputation quality, and correlation between 
imputed and direct genotype dosages were excellent, suggesting that our association findings 
were unlikely to be influenced by imputation quality. However, for rs16961023, the top SNP 
in the SLC10A2 region, imputation quality, and correlation between imputed and direct 
genotype dosages were similar, but only adequate, and there was a reduction in effect size 
when we repeated our association analysis among subjects with imputed posterior 
probabilities >0.8. It appears that subjects with less certain genotype probabilities may 
contribute disproportionately to the association signal, and, therefore, the SLC10A2 finding 
warrants cautious optimism. Finally, inclusion of low-frequency variants in GWAS can 
increase genomic inflation [56]. However, despite inclusion of low-frequency variants in our 
study, we did not see evidence of inflation (λ = 0.993, Supplementary Fig. 1).
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Although COBL and SLC10A2 are attractive candidate genes, variants identified through 
GWAS may not be causal and do not necessarily act at the gene closest to them. Therefore, it 
is only speculative that these genes are the causal risk factors for LOAD in AAs and that the 
identified variants have an effect on AD via the proposed regulatory mechanisms. Finally, 
our findings should be regarded with measured enthusiasm until they are confirmed in 
independent samples of AAs. Unfortunately, to our knowledge, additional large AA LOAD 
cohorts with genotype data are not currently available. Therefore, validation of the role of 
these loci in AD will likely require experimental evidence.
Taken together, these findings suggest that an informed conditioning approach can be used 
to identify new genetic associations for complex genetic traits where risk is a mix of genetic 
and environmental factors. Our success in using informed conditioning to identify new risk 
loci for AD mirrors the success of informed conditioning in GWASs of other phenotypes 
[11,12]. This work furthers our understanding of the biological underpinnings of AD in 
AAs. Functional studies are needed to determine whether COBL and SLC10A2 are suitable 
targets for development of novel therapies.
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RESEARCH IN CONTEXT
1. Systematic review: The authors are members of the Alzheimer’s Disease 
Genetics Consortium and therefore are familiar with emerging pertinent 
literature. PubMed searches were conducted to identify other relevant 
publications. References that informed the novel approach and that support 
the significance of the identified risk loci are cited.
2. Interpretation: Although >20 late-onset Alzheimer’s disease (LOAD) risk 
genes have been identified from genome-wide association studies (GWASs) 
for non-Hispanic whites, this report identifies only the third and fourth loci 
from GWAS associated with LOAD for African Americans (AAs). The 
COBL and SLC10A2 loci provide further evidence that axonal integrity and 
cholesterol homeostasis underlie LOAD pathophysiology.
3. Future directions: The study findings should be confirmed in independent AA 
samples. Unfortunately, additional large AA LOAD cohorts with genotype 
data are not currently available. Functional studies are needed to determine 
whether COBL and SLC10A2 are suitable targets for development of novel 
therapies.
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Fig. 1. 
(A) Regional association plot of the COBL region on chromosome 7 and (B) forest plots for 
rs112404845, the top single-nucleotide polymorphism in the region. Abbreviations: ACT, 
Adult Changes in Thought; ADC, Alzheimer’s Disease Center; ADGC, Alzheimer’s Disease 
Genetics Consortium; CHAP, Chicago Health and Aging Project; CI, confidence interval; 
COBL, Cordon-Bleu WH2 Repeat Protein; GenerAAtions, Genetic and Environmental Risk 
Factors for Alzheimer Disease among African Americans; and MAF, minor allele frequency.
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Fig. 2. 
(A) Regional association plot of the SLC10A2 region on chromosome 13 and (B) forest 
plots for rs16961023, the top single-nucleotide polymorphism in the region. Abbreviations: 
ACT, Adult Changes in Thought; ADC, Alzheimer’s Disease Center; ADGC, Alzheimer’s 
Disease Genetics Consortium; CHAP, Chicago Health and Aging Project; CI, confidence 
interval; GenerAAtions, Genetic and Environmental Risk Factors for Alzheimer Disease 
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among African Americans; MAF, minor allele frequency; and SLC10A2, solute carrier 
family 10, member 2.
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Table 1
Estimated conditional prevalence of AD in African Americans .65 years of age
Trait Conditional prevalence
Age
    65–74 0.062
    75–84 0.326
    ≥85 0.598
Sex
    Male 0.172
    Female 0.242
Education
    Low 0.305
    High 0.192
Current smoker
    No 0.190
    Yes 0.302
Diabetes
    No 0.188
    Yes 0.275
Overall 0.215
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